Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is positioned for success due to their innovative immuno-oncology pipeline and promising clinical stage programs, givastomig, uliledlimab, and ragistomig. Their approach of integrating business development and clinical research has resulted in a strong portfolio with depth and optionality, particularly with lead asset givastomig showing promising efficacy in combination with existing therapies in 1L HER2-negative metastatic gastric cancer patients. Additionally, their focus on patient data analysis, closely monitoring updates on clinical trials, and engaging with key opinion leaders in the field positions them for continued success in the biotechnology industry.

Bears say

NovaBridge Biosciences is facing potential challenges regarding the target patient population for its core product givastomig, as the majority of gastric cancer patients only have low-level expression of the CLDN18.2 biomarker. Additionally, there are concerns raised by KOLs about competing CLDN18.2 targeting strategies and infusion protocol complexities. These factors may hinder adoption and success of givastomig, impacting the company's overall prospects and financial performance.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.